Frequency and genotype distribution of hepatitis C virus infection in patients with diabetes type 2 in Ahvaz, Iran.
Diabetes mellitus type 2
Genotype
HCV
Prevalence
Journal
Iranian journal of microbiology
ISSN: 2008-3289
Titre abrégé: Iran J Microbiol
Pays: Iran
ID NLM: 101518404
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
14
12
2021
Statut:
ppublish
Résumé
Diabetes is recognized as a great concern and a public health problem worldwide. Several factors including environmental and genetic factors have been involved. Recently, infectious agents such as hepatitis C virus (HCV) have been reported to be associated with diabetes. Thus, this study was conducted to determine the frequency of HCV infection among patients with diabetes type 2 in Ahvaz city, Iran. A case-control study design was conducted at Ahvaz Jundishapur University of Medical Sciences. A total of 600 study subjects were included in this research. All the patient sera were tested for Anti-HCV antibody, HBsAg, and HIV antibody. The sera of positive Anti-HCV antibody, were assayed for 5'- UTR and core regions of the HCV genome by Nested RT-PCR. Finally, the HCV genotyping was determined by sequencing. The prevalence of HCV in type 2 diabetes and nondiabetic controls was 2% and 0.33%, respectively. The distribution of HCV genotypes among the HCV-positive patients were 3a (1.66%) and 1a (0.33%). To control and improve the treatment, the screening of HCV infection with anti-HCV antibody was followed by molecular techniques such as PCR and HCV genotyping which should be implemented for all patients with diabetes type 2.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Diabetes is recognized as a great concern and a public health problem worldwide. Several factors including environmental and genetic factors have been involved. Recently, infectious agents such as hepatitis C virus (HCV) have been reported to be associated with diabetes. Thus, this study was conducted to determine the frequency of HCV infection among patients with diabetes type 2 in Ahvaz city, Iran.
MATERIALS AND METHODS
METHODS
A case-control study design was conducted at Ahvaz Jundishapur University of Medical Sciences. A total of 600 study subjects were included in this research. All the patient sera were tested for Anti-HCV antibody, HBsAg, and HIV antibody. The sera of positive Anti-HCV antibody, were assayed for 5'- UTR and core regions of the HCV genome by Nested RT-PCR. Finally, the HCV genotyping was determined by sequencing.
RESULTS
RESULTS
The prevalence of HCV in type 2 diabetes and nondiabetic controls was 2% and 0.33%, respectively. The distribution of HCV genotypes among the HCV-positive patients were 3a (1.66%) and 1a (0.33%).
CONCLUSION
CONCLUSIONS
To control and improve the treatment, the screening of HCV infection with anti-HCV antibody was followed by molecular techniques such as PCR and HCV genotyping which should be implemented for all patients with diabetes type 2.
Identifiants
pubmed: 34900168
doi: 10.18502/ijm.v13i5.7437
pii: IJM-13-703
pmc: PMC8629818
doi:
Types de publication
Journal Article
Langues
eng
Pagination
703-711Informations de copyright
Copyright © 2021 The Authors. Published by Tehran University of Medical Sciences.
Références
BMC Infect Dis. 2020 Sep 9;20(1):664
pubmed: 32907538
J Res Med Sci. 2013 Aug;18(8):674-82
pubmed: 24379843
Ann Intern Med. 2000 Oct 17;133(8):592-9
pubmed: 11033586
World J Gastroenterol. 2016 Sep 28;22(36):8094-102
pubmed: 27688651
J Pak Med Assoc. 2002 Jul;52(7):280-3
pubmed: 12481656
Am J Epidemiol. 2003 Dec 15;158(12):1154-60
pubmed: 14652300
Interdiscip Perspect Infect Dis. 2012;2012:354656
pubmed: 23049551
J Investig Med. 2008 Aug;56(6):858-63
pubmed: 18667903
World J Gastroenterol. 2012 Apr 14;18(14):1642-51
pubmed: 22529694
World J Gastroenterol. 2015 Oct 14;21(38):10790-810
pubmed: 26478671
Diabetes Res Clin Pract. 2000 May;48(2):147-51
pubmed: 10802152
Diabetes Res Clin Pract. 2014 Feb;103(2):137-49
pubmed: 24630390
J Natl Med Assoc. 2006 Nov;98(11):1805-8
pubmed: 17128691
Hepatology. 2003 Dec;38(6):1384-92
pubmed: 14647049
Diabetes Res Clin Pract. 2007 Mar;75(3):320-6
pubmed: 16919355
Liver Int. 2009 Mar;29 Suppl 2:13-25
pubmed: 19187069
Braz J Med Biol Res. 2012 Mar;45(3):284-90
pubmed: 22286533
J Diabetes Res. 2013;2013:539361
pubmed: 23984431
Lancet Infect Dis. 2005 May;5(5):296-304
pubmed: 15854885
J Chin Med Assoc. 2006 Apr;69(4):146-52
pubmed: 16689194
World J Gastroenterol. 2014 Jun 28;20(24):7555-69
pubmed: 24976696
Gut. 2007 Aug;56(8):1105-10
pubmed: 16956918
Rev Med Inst Mex Seguro Soc. 2012 Sep-Oct;50(5):481-6
pubmed: 23282259
Diabetes Care. 2013 Jan;36 Suppl 1:S67-74
pubmed: 23264425
World J Gastroenterol. 2014 Nov 7;20(41):15233-40
pubmed: 25386071
J Clin Microbiol. 1997 Jan;35(1):201-7
pubmed: 8968908
Indian J Med Microbiol. 2014 Jul-Sep;32(3):251-5
pubmed: 25008816
Niger J Clin Pract. 2008 Jun;11(2):94-9
pubmed: 18817046
Can J Gastroenterol Hepatol. 2018 Aug 13;2018:6150861
pubmed: 30186821
J Virol. 2007 Feb;81(4):1727-35
pubmed: 17135326
World J Gastroenterol. 2016 Sep 14;22(34):7824-40
pubmed: 27678366
World J Gastroenterol. 2009 Apr 7;15(13):1537-47
pubmed: 19340895
Med Res Rev. 2009 Nov;29(6):843-66
pubmed: 19378287
Indian J Med Microbiol. 2017 Apr-Jun;35(2):262-268
pubmed: 28681817
JAMA. 2003 Mar 12;289(10):1245-6
pubmed: 12633185
J Ayub Med Coll Abbottabad. 2007 Jan-Mar;19(1):46-9
pubmed: 17867480
Hepatology. 2013 Apr;57(4):1333-42
pubmed: 23172780
Braz J Infect Dis. 2008 Feb;12(1):24-6
pubmed: 18553010
Clin Infect Dis. 2003 May 15;36(10):1318-23
pubmed: 12746779
Arch Iran Med. 2012 May;15(5):268
pubmed: 22519372
Virol J. 2009 Jul 08;6:98
pubmed: 19586535
Hepatology. 2002 Dec;36(6):1439-45
pubmed: 12447870